MAP
SRPT icon

Moody Aldrich Partners’s Sarepta Therapeutics SRPT Stock Holding History

Moody Aldrich Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,335
Closed -$432K – 236
2024
Q1 		$432K Sell
3,335
-3,821
-53% -$468K 0.07% 150
2023
Q4 		$690K Sell
7,156
-71
-1% -$6.81K 0.12% 122
2023
Q3 		$876K Buy
+7,227
New +$817K 0.17% 118
2016
Q4 		– Sell
-20,085
Closed -$1.23M – 102
2016
Q3 		$1.23M Buy
+20,085
New +$607K 0.86% 64

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Moody Aldrich Partners's SRPT Position: Q2 2024 in Review

Moody Aldrich Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 3,335 shares — an estimated $432K sold.

Moody Aldrich Partners first reported a position in SRPT in Q3 2016 and held it in 4 quarters. The position peaked at $1.23M in Q3 2016. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Moody Aldrich Partners reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 3,335 Sarepta Therapeutics shares in Q2 2024, an estimated $432K.
  • Moody Aldrich Partners first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 4 quarters.
  • Moody Aldrich Partners's Sarepta Therapeutics position peaked at $1.23M in Q3 2016.
  • 483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.